Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819936 | 1.00 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL5411482 | 1.00 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL15113629 | 0.95 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL12158537 | 0.95 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL13979660 | 0.90 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL3796359 | 0.90 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL13827672 | 0.85 | POLB (0.53) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL8478457 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL12018731 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL8478452 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-8563533-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
| US-8268880-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | HSD17B10 4439/4885SMN1; SMN2 14/4885NPC1 1929/4885 |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AADAC, NAT1, PMP22 | HSD17B10 487/4885SMN1; SMN2 8/4885NPC1 1645/4885 |
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | PREP, DPP4, PEPD | HSD17B10 3603/4885SMN1; SMN2 1442/4885NPC1 2802/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HSD17B10 2499/4885SMN1; SMN2 4705/4885NPC1 414/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HSD17B10 2646/4885SMN1; SMN2 4657/4885NPC1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.